SCHEMBL23979677

SCHEMBL23979677

CSc1nc2c(c(N3CCN(C(=O)OC(C)(C)C)CC3)n1)CCN2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 1/20 0.39
GBA1 P04062 2/20 0.39
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38
KIT P10721 2/20 0.38
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
CKS1B P61024 1/20 0.37
SKP1 P63208 1/20 0.37
SKP2 Q13309 1/20 0.37
TLR9 Q9NR96 1/20 0.37
GPR119 Q8TDV5 3/20 0.36
ACHE P22303 1/20 0.36
ALDH1A1 P00352 2/20 0.36
MAPT P10636 2/20 0.36
LMNA P02545 1/20 0.36
KDM4E B2RXH2 1/20 0.36
USP2 O75604 1/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23979654 0.94 GBA1 (0.39) CXCR2GBA1CCNA2CDK2KIT
SCHEMBL19949022 0.83 CCNA2 (0.41) CXCR2GBA1CCNA2CDK2KIT
SCHEMBL21722183 0.80 GBA1 (0.44) CXCR2GBA1CCNA2CDK2CKS1B
SCHEMBL8340940 0.78 GBA1 (0.41) GBA1KITDDB1CRBNCKS1B
SCHEMBL25771136 0.77 CXCR2 (0.38) CXCR2GBA1CCNA2CDK2KIT
SCHEMBL31600917 0.76 SMPD3 (0.43) KITDDB1CRBNCKS1BSKP1
SCHEMBL23979710 0.74 CHRNA7 (0.41) CXCR2GBA1CCNA2CDK2KIT
SCHEMBL21722244 0.74 CCNA2 (0.39) CXCR2GBA1CCNA2CDK2KIT
SCHEMBL30177806 0.74 CCNA2 (0.39) CXCR2GBA1CCNA2CDK2KIT
SCHEMBL19964211 0.73 MTOR (0.45) GBA1CCNA2CDK2TLR9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021219072-A1 PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR 上海科州药物研发有限公司 (CN) 2021-11-04 WO disclosed